Lexicon Pharmaceuticals (LXRX) News Today → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free LXRX Stock Alerts $1.77 0.00 (0.00%) (As of 05:07 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | americanbankingnews.comShort Interest in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Increases By 16.5%May 16, 2024 | marketbeat.comLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Short Interest UpdateLexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the recipient of a large increase in short interest during the month of April. As of April 30th, there was short interest totalling 23,440,000 shares, an increase of 16.5% from the April 15th total of 20,120,000 shares. Based on an average trading volume of 4,450,000 shares, the short-interest ratio is currently 5.3 days.May 15, 2024 | money.usnews.comLexicon Pharmaceuticals IncMay 14, 2024 | globenewswire.comNew Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection FractionMay 14, 2024 | americanbankingnews.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Passes Above Two Hundred Day Moving Average of $1.77May 9, 2024 | globenewswire.comLexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024May 4, 2024 | markets.businessinsider.comOptimistic Buy Rating for Lexicon Pharmaceuticals Amid Strong Inpefa Sales Outlook and Efficient Financial ManagementMay 4, 2024 | markets.businessinsider.comLexicon Pharmaceuticals Reports Q1 Loss, Misses Revenue EstimatesMay 3, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Receives Hold Rating from Needham & Company LLCNeedham & Company LLC reiterated a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Friday.May 3, 2024 | finance.yahoo.comLexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 3, 2024 | msn.comBiomea Fusion GAAP EPS of -$1.09 misses by $0.02May 2, 2024 | finance.yahoo.comLexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...May 2, 2024 | msn.comLXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024May 2, 2024 | globenewswire.comLexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | marketbeat.comLexicon Pharmaceuticals' (LXRX) Outperform Rating Reaffirmed at Leerink PartnrsLeerink Partnrs reissued an "outperform" rating on shares of Lexicon Pharmaceuticals in a report on Tuesday.May 1, 2024 | msn.comLeerink Partners Initiates Coverage of Lexicon Pharmaceuticals (LXRX) with Outperform RecommendationApril 30, 2024 | marketbeat.comLexicon Pharmaceuticals (LXRX) to Release Earnings on ThursdayLexicon Pharmaceuticals (NASDAQ:LXRX) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=372983)April 30, 2024 | markets.businessinsider.comLexicon Pharmaceuticals CEO Lonnel Coats To RetireApril 30, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at SVB LeerinkSVB Leerink began coverage on shares of Lexicon Pharmaceuticals in a report on Tuesday. They issued an "outperform" rating and a $5.00 price objective for the company.April 29, 2024 | finanznachrichten.deLexicon Pharmaceuticals, Inc.: Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsApril 29, 2024 | marketwatch.comLexicon Pharmaceuticals Chief Executive Lonnel Coats to Retire in JulyApril 29, 2024 | globenewswire.comLonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsApril 29, 2024 | finance.yahoo.comLexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024April 23, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Alvotech (ALVO), Cardinal Health (CAH)April 23, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Earns Hold Rating from Needham & Company LLCNeedham & Company LLC reaffirmed a "hold" rating on shares of Lexicon Pharmaceuticals in a report on Tuesday.April 18, 2024 | globenewswire.comLexicon Pharmaceuticals to Host 2024 Investor DayApril 11, 2024 | marketbeat.comLexicon Pharmaceuticals' (LXRX) Hold Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Lexicon Pharmaceuticals in a research note on Thursday.April 4, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 5.9%Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.9%April 3, 2024 | finance.yahoo.comLexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceApril 1, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 3.7% Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 3.7%March 27, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Trading Up 11.1%Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Up 11.1%March 25, 2024 | globenewswire.comClinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoMarch 22, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 5.8%Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 5.8%March 16, 2024 | finance.yahoo.comLXRX Apr 2024 5.000 putMarch 12, 2024 | marketbeat.comLexicon Pharmaceuticals (NASDAQ:LXRX) Shares Down 6.8% Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading Down 6.8%March 12, 2024 | markets.businessinsider.comLexicon Announces Positive Data Of InTandem3 Study In Type 1 Diabetes Patients With CKD; Stock DownMarch 12, 2024 | seekingalpha.comLexicon stock slides 8% after rallying 30% in prior sessionMarch 12, 2024 | finance.yahoo.comNew Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseMarch 12, 2024 | seekingalpha.comLexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core AssetMarch 11, 2024 | marketbeat.comStock Traders Purchase High Volume of Call Options on Lexicon Pharmaceuticals (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the target of unusually large options trading on Monday. Stock traders purchased 7,172 call options on the company. This is an increase of approximately 264% compared to the typical daily volume of 1,970 call options.March 11, 2024 | marketwatch.comLexicon Pharmaceuticals Shares Rise on Beat to 4Q Loss, Plans for SotagliflozinMarch 11, 2024 | finance.yahoo.comLexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDAMarch 11, 2024 | washingtonpost.comLexicon: Q4 Earnings SnapshotMarch 11, 2024 | benzinga.comLexicon Pharmaceuticals: Q4 Earnings InsightsMarch 11, 2024 | globenewswire.comLexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business UpdateMarch 11, 2024 | globenewswire.comLexicon Announces Oversubscribed $250 Million Private Placement of Equity SecuritiesMarch 8, 2024 | marketbeat.comFmr LLC Has $8.24 Million Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)Fmr LLC decreased its position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 11.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,563,076 shares of the biopharmacFebruary 23, 2024 | marketbeat.comTraders Purchase High Volume of Lexicon Pharmaceuticals Call Options (NASDAQ:LXRX)Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) was the recipient of some unusual options trading activity on Friday. Stock investors purchased 5,137 call options on the stock. This represents an increase of 212% compared to the typical daily volume of 1,647 call options.February 22, 2024 | finance.yahoo.com15 Hot Penny Stocks On the MoveFebruary 21, 2024 | marketbeat.comClariVest Asset Management LLC Sells 318,976 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)ClariVest Asset Management LLC lowered its stake in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Free Report) by 62.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 192,398 shares of the Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking $16T Elon Musk Crypto Leak (Ad)Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run. Click here now to get your copy. LXRX Media Mentions By Week LXRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXRX News Sentiment▼0.480.42▲Average Medical News Sentiment LXRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXRX Articles This Week▼52▲LXRX Articles Average Week Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: VSTM News VNDA News XOMA News EBS News MACK News RIGL News RGLS News RZLT News OPK News INVA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXRX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority Gold"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
